Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response
Li, E., et al., Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response
- Categories
- Peer Reviewed Publications
Categories
Filter by Topics
1L therapy; bispecific antibodies ABC- type AI alcohol consumption ALK alzheimer's Angiogenesis angiosarcoma antibody drug conjugates Apoptosis appendiceal neoplasms Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells B-accute lyphoblastic leukemia B-ALL B-cell lymphoma bacterial vaginosis BCL2A1 BCL6 benign bile acids Biofluid biomarker Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation biomarkers Biomarkers Bladder Bladder Cancer Bladder cancer blastoid morphology blindness breast cancer Breast Cancer Breast milk Breast Milk Burkitt lymphoma Cancer Genomics CAR-T-cells Castleman Disease CD10 CD8 CDK CDK46 inhibitors CDKN1A Cells Cerebrospinal Fluid cervix Cetuximab chemotherapy Childhood Atopic Dermatitis children Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating tumor cells Clinical Trial clinical trial cognition Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA Cytokine Cytokines Cytotoxic T Cells dementia Dementia Diabetes Differential Expression Differential Gene Expression Analysis diffuse large B-cell lymphoma DLBCL DLBCL COO Drug Response Drug Safety Drug Targets Drug-induced Liver Injury dysbiosis Dysplasia ear EGFR Muatations EMT Endothelial cell epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epithelial–mesenchymal plasticity Epstein-Barr Esophageal Cancer estrogen receptor 1 ESR1 exosome Exosomes Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease farnesoid X receptorcholesterol Feasibility female reproductive tract FFPE FGF Ligand Trap fibroblast growth factor receptor 4 Fibrous Tumors FOLFOX7 gastrointestinal cancer Gene expression analysis Gene Expression Profiling gene expression signature Gene Signature Analysis Glioblastoma Tumors glucocorticoid receptor NR3C1 HARMONIA clinical trial HCC Head and neck cancer Head and Neck Cancer Heart hematologic or solid tumors hepatocellular carcinoma HER HER2 Heterogeneity histone methyltransferase HLA-E HPV HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune Tolerance Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours immunoscore immunotherapy Immunotherapy Inflammation inhibitor Insulin Resistance Intrinsic subtypes IOA-244 IRF4 IRS-1 JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Lactobacillus crispatus Limb ischemia limbal stem cell deficiency LSCD Liquid Biopsy Liver liver disease liver steatosis Lung Lung cancer Lymph Node Metastasis lymphatic Lymphoid Neoplasia Lymphoma Machine Learning machine learning malignant Mechanism of Action Melanoma Mesothelioma MET metastatic breast cancer MBC metastatic colorectal cancer CRC MIBC Microenvironment MicroRNA microRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization molecular subtypes Mouse Mouse mRNA mouse mRNA TRP mRNA mRNA custom mTOR pathway multi-omics MUM1 Muscle Muscle-invasive bladder cancer Mutations NAFLD Nash and Fibrosis Nature Neoantigens Neuroendocrine Tumor Neurologic NKG2A Non-alcoholic fatty liver disease non-Hodgink Lymphoma Non-small cell lung cancer nuclease protection assay obesity Obesity OBP Oncology Oncology-Biomarker OPSCC Optical imaging Oral cancer Oral Cancer Oral cavity Oral lesion Oral Squamous Cell Carcinoma Oropharyngeal Cancer Osteoclast Ovarian cancer PAM50 Predictive biomarkers Pan-Cancer Pancreas Pancreatic Cancer Paralysis Partial EMT Pathogenesis pathophysiology Pathway Analysis Pathway analysis PBMCs PCA Cell Lines PD-1 PD-L1 PEARL PFAS PFNA PFOS Phase III PHOENIX trial PI3K PIP placenta Placenta Plasma Plasma miRNAs PMAIP1 population based Precision medicine Precision oncology predictive biology Predictive Biomarkers Predictive Modeling Prevotella bivia Progression free-survival Prostate Prostate Cancer qNPA R-CHOP Refractory DLBCL Relapsed DLBCL renal cell carcinoma Reproductive Response rate Reveal Rhabdomyosarcoma RMS Rheumatoid Arthritis Risk Score Sarcoma sarcoma SARS-CoV-2 scoring system Sequencing Serum Signaling Inhibitors Signatures single cell Single-cell RNA Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma STD Sub-typing surface plasmon Surveillance Survival Outcomes Synovial Fluid Synovial Sarcoma synthetic miRNA T-Cell T-cells targeted therapeutics Technology Comparison Therapeutic targets Thyroid Cancer tislelizumab TMB tomentosin Toxicity Transcriptome transcriptome profile transcriptome profiling Translational Medicine Treatment Outcome Trichomonas vaginalis Tumor Biology Tumor Heterogeneity Tumor Microenvironment Urothelial carcinoma Uterus vagina vestibular schwannoma VS virus Waldeyer's ring Wound healing Xenograft Tissue ZEB12021
Page last updated May 22, 2023